Industry hails Union Budget 2024-25

The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable

Budget 2024-25: Industry expects push for reforms, R&D and fiscal incentives

Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23

Singhi Advisors facilitates acquisition of 85% stake of GMP Technical Solutions by Japanese Shinryo Corporation

This transaction is the third acquisition by three different Japanese players in this segment

Zydus signs patent licensing agreement with Takeda for 'VaultA’ in India

The pooled prevalence of GERD in the Indian population is 15.6 %

Kwality Pharmaceuticals receives DIGIMED approval for generic, injectable and OSD

Kwality Pharma already has registration of 20 molecules from the units and 20 are under registration

Dr. Reddy's signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan

Merck starts commercial production of first GMP-compliant manufacturing line for cell culture media in China

€ 6.6 million investment at Nantong site expands production capabilities for cell culture media

Biostar Pharma gets FDA clearance of the IND application for a Phase 2 study of Utidelone Injection

Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux

Ligand to acquire Apeiron Biologics for US$100 million

Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.

Nephro Care India lists at 90% premium

NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90